This large prospective cohort study compares the rates of acute myocardial infarction between recipients of a 2-dose hepatitis B vaccine and recipients of a 3-d
Soligenix Announces Recent Accomplishments And First Quarter 2021 Financial Results
News provided by
Share this article
Share this article
PRINCETON, N.J., May 17, 2021 /PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2021. This year continues to be an exciting year of progress for Soligenix, stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. We recently announced presentation of clinical data from our successful pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) clinical trial for HyBryte™ (SGX301) in the treatment of cutaneous T-cell lymphoma (CTCL) at both the American Academy of Dermatology, where HyBryte™ was designated Top 12 late-breaking
Operator
Good day, ladies and gentlemen, and welcome to the Dynavax Technologies first-quarter 2021 conference call. As a reminder, this conference call is being recorded. At the end of the company s prepared remarks, we will open the call for questions and provide specific instructions at that point. I would now like to turn the call over to Nicole Arndt, senior manager, investor relations.
You may begin.
Senior Manager, Investor Relations
Thank you, operator. Good afternoon. Welcome to the Dynavax first-quarter 2021 financial results and corporate update conference call. Joining me on the call today are Ryan Spencer, chief executive officer; Kelly MacDonald, chief financial officer; Robert Janssen, chief medical officer; and Donn Casale, senior vice president, commercial.
/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.
Two HEPLISAV-B Abstracts Selected for Oral Presentation at the 2021 Annual Conference on Vaccinology Research (ACVR) prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.